Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy and safety of intravitreal ranibizumab injection versus low-fluence PDT in the treatment of chronic CSC.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jang Won Heo
• Collaborator: Novartis Korea Ltd.
• Treatments: Lactitol; Ranibizumab; Verteporfin

Criteria

Inclusion Criteria:

1. best-corrected visual acuity (BCVA) between 0.0 and 1.0 logarithm of the minimal angle of resolution (logMAR)

2. presence of subfoveal fluid persisting for 3 months or more on optical coherence tomography (OCT)

3. presence of leakage and multifocal/diffuse RPE decompensation on fluorescein angiography (FA)

4. choroidal vascular hyperpermeability and abnormal dilation of choroidal vasculature on indocyanine angiography (ICGA)

Exclusion Criteria:

1. previous treatment, such as laser photocoagulation, PDT, intravitreal injection of steroid or anti-VEGF agent

2. evidence of choroidal neovascularization

3. any other ocular diseases that could affect visual acuity

4. systemic steroid treatment in the previous 12 months

5. media opacity such as cataract that could interfere with adequate acquisition of OCT, FA and ICGA images